lpx-ti641
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2023 (NCT05853835)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06982352 | Phase 1 | Jun 15, 2025 | LAPIX Therapeutics Inc. |
| NCT06628206 | Phase 1 | Nov 15, 2024 | LAPIX Therapeutics Inc. |
| NCT05853835 | Phase 1 | Oct 30, 2023 | LAPIX Therapeutics Inc., Triumpharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LAPIX Therapeutics Inc. | For profit | 3 | 3 | 1 | 2023 |
| Triumpharma | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1